GPR109A Blocking Peptide – Cat# MBS8309512

GPR109A Blocking Peptide – >85% Purity

Name: GPR109A Blocking Peptide; >85% Purity; MyBioSource
Brand: MyBioSource
SKU: MBS8309512
Price: 230 USD
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS8309512

MBS8309512 is a blocking peptide targeting HCAR2. Also known as GPR109A Blocking Peptide. Reactive in Human, Mouse, Rat. Host: Synthetic. The peptide is used to block Anti-GPR109A Antibody reactivity. More details

$230 / 1 mg +1 FREE 8GB USB

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

GPR109A (HCAR2), Blocking Peptide

Full Product Name

GPR109A Blocking Peptide

Product Gene Name

HCAR2 blocking peptide

Product Synonym Names

HCAR2; GPR109A; HCA2; HM74A; NIACR1; Hydroxycarboxylic acid receptor 2; G-protein coupled receptor 109A; G-protein coupled receptor HM74A; Niacin receptor 1; Nicotinic acid receptor

Host

Synthetic

Species Reactivity

Human, Mouse, Rat

Form/Format

Lyophilized Powder

Purity/Purification

>85%

Preparation and Storage

Store at -20 degree C for one year.

Molecular Weight

41,850 Da

Quality Control

The quality of the peptide was evaluated by reversed-phase HPLC and by mass spectrometry.

Directions for Use

Blocking Peptide to the diluted primary antibody in a molar ratio of 10:1 (peptide to antibody) and incubate the mixture at 4 degree C for overnight or at room temperature for 2 hours.

Applications Tested/Suitable for HCAR2 blocking peptide

Blocking (BL)

Other Notes

Small volumes of HCAR2 blocking peptide vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Additional Details

NCBI/Uniprot data below describe general gene information for HCAR2. It may not necessarily be applicable to this product.

NCBI GI #

152112976

NCBI GeneID

338442

NCBI Accession #

ABS29270.1

UniProt Primary Accession #

Q8TDS4

UniProt Secondary Accession #

Q9EP66; Q80Z39

UniProt Related Accession #

Q8TDS4

NCBI Official Full Name

G protein-coupled receptor 109A

NCBI Official Synonym Full Names

hydroxycarboxylic acid receptor 2

NCBI Official Symbol

HCAR2

NCBI Official Synonym Symbols

HCA2; HM74a; HM74b; PUMAG; NIACR1; Puma-g; GPR109A

UniProt Protein Name

Hydroxycarboxylic acid receptor 2

UniProt Synonym Protein Names

G-protein coupled receptor 109A; G-protein coupled receptor HM74A; Niacin receptor 1; Nicotinic acid receptor

Protein Family

Hydroxycarboxylic acid receptor

UniProt Gene Name

HCAR2

UniProt Synonym Gene Names

GPR109A; HCA2; HM74A; NIACR1

NCBI Protein Information

hydroxycarboxylic acid receptor 2

UniProt Comments for HCAR2

Acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis. The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide.

Research Articles on HCAR2

1. GPR109A may inhibit inflammatory cytokine production, induced by palmitic acid, by MIN6 cells possibly via inhibiting the Akt/mTOR signaling pathway.

Precautions

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

Disclaimer

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.

Product Note

Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual, it is intended to serve as an example only. Please refer to the instructions For Use provided with the assay kit for precise details.

Product PubMed Publications

Diseases associated with HCAR2 blocking peptide

Disease Name	Pubmed Publications
Flushing Antibodies	>31 publications with HCAR2 and Flushing
Atherosclerosis Antibodies	>16 publications with HCAR2 and Atherosclerosis
Dyslipidemias Antibodies	>10 publications with HCAR2 and Dyslipidemias
Arteriosclerosis Antibodies	>6 publications with HCAR2 and Arteriosclerosis
Inflammation Antibodies	>6 publications with HCAR2 and Inflammation
Neoplasms Antibodies	>5 publications with HCAR2 and Neoplasms
Psoriasis Antibodies	>3 publications with HCAR2 and Psoriasis
Carcinoma, Squamous Cell Antibodies	>3 publications with HCAR2 and Carcinoma, Squamous Cell
Coronary Disease Antibodies	>2 publications with HCAR2 and Coronary Disease
Skin Neoplasms Antibodies	>2 publications with HCAR2 and Skin Neoplasms

Organs/Tissues associated with HCAR2 blocking peptide

Organ/Tissue Name	Pubmed Publications
Blood Antibodies	>24 publications with HCAR2 and Blood
Skin Antibodies	>16 publications with HCAR2 and Skin
Adipose Tissue Antibodies	>10 publications with HCAR2 and Adipose Tissue
Liver Antibodies	>9 publications with HCAR2 and Liver
Lung Antibodies	>7 publications with HCAR2 and Lung
Intestine Antibodies	>4 publications with HCAR2 and Intestine
Brain Antibodies	>3 publications with HCAR2 and Brain
Eye Antibodies	>2 publications with HCAR2 and Eye
Spleen Antibodies	>2 publications with HCAR2 and Spleen
Muscle Antibodies	>1 publications with HCAR2 and Muscle